Designing ADCs through phosphonate payload and linker optimization

Image Caption

 

“...there lies an opportunity to expand the clinical potential of ADCs by combining the cytotoxic warheads with immunostimulatory payloads.”

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Mary van Helden, Director Immuno-Oncology, Byondis, about the development of immuno-stimulatory phosphonate-ADCs, the biological rationale for targeting γδ T cells through butyrophilin-mediated signaling, and how advances in linker chemistry and payload design are shaping the next generation of immune-engaging ADCs.

Please enter your email to access content Read now